Physician profile
Jody George
NPI 1568592368
$9,856.55
in general payments reported to CMS, 2019-2025
44 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $864 · 2021: $1,327 · 2022: $1,324 · 2023: $1,717 · 2024: $1,765 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.39 |
| Education | $128.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.61 | 2021-2025 | |
| Corium, LLC | $910.10 | 2021-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $751.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $619.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $543.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $506.79 | 2019-2025 | |
| Amgen INC. | $474.92 | 2019-2025 | Prolia, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $420.34 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Sanofi-Aventis U.S. LLC | $394.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.56 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $377.61 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $345.76 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $325.77 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $314.19 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $261.13 | 2021-2025 | Leqvio |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.